Deals In Depth: October 2017
Eli Lilly made a big commitment to immuno-oncology with its $1.8 billion deal for CureVac's mRNA vaccines. Amneal and Impax merged, creating the fifth-largest generics company in the US. Billion-dollar aggregates were reached in FOPOs, debt, and late-stage venture pharma financing.
You may also be interested in...
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.